NCT03442569 - PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

September 21, 2020

Study Completion Date

December 2, 2024

Conditions

Colon Cancer

Interventions

DRUG

Panitumumab

6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab

DRUG

Nivolumab

240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab

DRUG

Ipilimumab

1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab

Trial Locations (5)

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill

Moffitt Cancer Center, Tampa

Vanderbilt University Medical Center, Nashville

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis

University of Washington - Seattle Cancer Care Alliance, Seattle